Drug Pricing

Jim Cramer has raised concerns over the constitutionality of recent drug price controls, urging pharmaceutical companies to seek an injunction. What Happened:  CNBC’s Mad Money host, Cramer, in a post on X on Monday, argued that, unlike tariffs, drug price controls fall under the...

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. What Happened: The Trump Administration is contemplating a policy to align U.S. drug prices with lower rates in other developed countries. The policy is likely to...

Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump‘s 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs) in the U.S. healthcare system. What Happened: In a post on X, addressed to President Trump...

Health and Human Services Secretary Alex Azar and the Food and Drug Administration announced Wednesday that the Trump administration has dropped a long-standing resistance to importing drugs and outlined a plan that could eventually allow the importation of some cheaper prescription drugs from...

The Trump administration will no longer proceed with a large-scale overhaul of the drug-rebate industry. What Happened Pharmacy benefit managers (PBMs) negotiate a drug discount on behalf of health insurers and collect a commission for themselves as profit. Critics of the system argued it gives...

President Donald Trump has nominated Alex Azar, a former pharmaceutical executive, to run the Department of Health and Human Services. What You Need To Know The Department of Health and Human Services is a cabinet-level department of the U.S. federal government with a mission of protecting...

Express Scripts Holding Company (NASDAQ: ESRX) saw its stock lose nearly 2 percent Wednesday after Sen. Ron Wyden proposed a legislation which would require drug middlemen, like Express Scripts, from disclosing otherwise secret discounts they receive from drug manufacturers. According to a...

As was widely documented, the healthcare sector languished last year thanks in large part to presidential election rhetoric in which both candidates excoriated biotechnology and pharmaceuticals for high drug prices. The Health Care SPDR (ETF) (NYSE: XLV), the largest healthcare exchange-traded fund...

Lannett Company, Inc. (NYSE: LCI) was trading lower by more than 5 percent Tuesday after Citron Research slammed the distributor of generic drugs in a new report. According to Citron, Lannett will become the first pharmaceutical company to go bankrupt and its equity is worth $13 to $15 a share...

Mylan NV (NASDAQ: MYL) faced its fair share of controversy earlier this year for increasing the price of its potentially life-saving EpiPen product by more than 400 percent over the past few years. On Friday, Mylan announced the launch of the authorized generic for EpiPen at a wholesale acquisition...

The U.S. Justice Department accused two generic pharmaceutical executives of colluding with each other to fix prices. According to a Bloomberg report, Jeffrey Glazer, the ex-CEO Heritage Pharmaceuticals, and Jason Malek, an ex-president of the company, were accused of conspiring with executives at...

Pharmaceutical companies breathed a sigh of relief when Donald Trump prevailed on Election Day. His opponent, Hillary Clinton, had made prescription drug pricing a centerpiece of her campaign. However, according to Bernstein analyst Tim Anderson, pharma stocks may not be off the hook when Trump...

Sen. Bernie Sanders and President-elect Donald Trump don't agree on much, but they seem to have found some middle-ground when it comes to drug prices. Sanders said in a press release Tuesday that he proposed an amendment that would lower the cost of prescription drugs by allowing Medicare...

Biotech investors thought they dodged a bullet on Election Day, but drug prices may soon be back in the spotlight. Time just named President-elect Donald Trump its 2016 Person of the Year. In an interview with Time, Trump was asked about prescription drug prices. “I’m going to...

Shares of Pfizer Inc. (NYSE: PFE) were little changed after the company said it will appeal a $106 million fine by the United Kingdom's competition regulator, the Competition and Markets Authority (CMA). According to The Wall Street Journal, Pfizer was slapped with a £84.2 million...